A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy-Reference-Cited by-同舟云学术

A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy

Published:2017-01 Issue:1 Volume:4 Page:grhta.5000274
ISSN:2284-2403
Container-title:Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish
language:en
Short-container-title:Global & Regional Health Technology Assessment

Author:

Iannazzo Sergio¹,Distante Chiara¹,Lopatriello Stefania¹,Bordonaro Roberto²

Affiliation:

1. SIHS Health Economics Consulting, Turin - Italy

2. U.O.C. Oncology Department, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania - Italy

Publisher

Aboutscience Srl

Subject

Health Policy

Link

http://journals.sagepub.com/doi/pdf/10.5301/grhta.5000274

Reference33 articles.

1. World Health Organization (WHO). Cancer fact sheet Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed October 7, 2017.

2. National Cancer Institute (NIH). Colorectal cancer – patient version http://www.cancer.gov/types/colorectal. Accessed October 7, 2017.

3. Associazione Italiana di Oncologia Medica (AIOM) (The Italian Association of Medical Oncology). Linee guida, tumori del colon retto. Edizione 2015 http://www.aiom.it/professionisti/documenti-scientifici/linee-guida/colon-retto/1,723,1.

4. Evolving Treatment of Advanced Colon Cancer

5. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran;Cancer Control;2023-04

2. Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project;Cancers;2020-03-31